<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548862" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548862/" /><meta name="ncbi_pagename" content="Enfuvirtide - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Enfuvirtide - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Enfuvirtide" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2018/02/10" /><meta name="citation_pmid" content="31644169" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548862/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Enfuvirtide" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2018/02/10" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548862/" /><meta name="description" content="Enfuvirtide is an HIV fusion inhibitor, the first of this class of agents active against the human immunodeficiency virus (HIV). Enfuvirtide has not been associated with serum aminotransferase elevations during therapy or episodes of acute, clinically apparent liver injury." /><meta name="og:title" content="Enfuvirtide" /><meta name="og:type" content="book" /><meta name="og:description" content="Enfuvirtide is an HIV fusion inhibitor, the first of this class of agents active against the human immunodeficiency virus (HIV). Enfuvirtide has not been associated with serum aminotransferase elevations during therapy or episodes of acute, clinically apparent liver injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548862/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Enfuvirtide/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548862/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8A34C804654F61000000000A580335.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548862_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548862_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Enflurane/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Entacapone/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548862_"><span class="title" itemprop="name">Enfuvirtide</span></h1><p class="small">Last Update: <span itemprop="dateModified">February 10, 2018</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Enfuvirtide.OVERVIEW"><h2 id="_Enfuvirtide_OVERVIEW_">OVERVIEW</h2><div id="Enfuvirtide.Introduction"><h3>Introduction</h3><p>Enfuvirtide is an HIV fusion inhibitor, the first of this class of agents active against the human immunodeficiency virus (HIV). Enfuvirtide has not been associated with serum aminotransferase elevations during therapy or episodes of acute, clinically apparent liver injury.</p></div><div id="Enfuvirtide.Background"><h3>Background</h3><p>Enfuvirtide (en fue' vir tide) is relatively new antiretroviral drug that blocks the fusion of HIV to target cell, preventing viral entry and subsequent infection. Enfuvirtide is a 36 amino acid biomimetic peptide that resembles the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. Enfuvirtide has both in vitro and in vivo activity against HIV, and several randomized controlled trials have shown that it leads to significant decline in HIV RNA levels and rises in peripheral CD4 T cell counts. Enfuvirtide was approved for use in the United States in 2003, but it has had limited use, partially because it requires parenteral administration once or twice daily. Enfuvirtide is available in single use vials that contain 90 mg/mL after reconstitution under the brand name of Fuzeon. The recommended regimen for enfuvirtide is 90 mg subcutaneously twice daily in adults and 2 mg/kg in children ages 6 to 16. Enfuvirtide is recommended only in combination with other antiretroviral agents. The only common side effects specifically linked to enfuvirtide have been injection site reactions (which can be troublesome) and eosinophilia. Regimens that include enfuvirtide have the potential to cause immune reconstitution syndrome, pneumonitis and severe hypersensivity reactions.</p></div><div id="Enfuvirtide.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Enfuvirtide has not been reported to cause serum aminotransferase elevations at rates higher than in controls receiving similar antiretroviral therapy. No instances of clinically apparent liver injury due to enfuvirtide have appeared in the published literature. Enfuvirtide has, however, not been a widely used agent. Partially because it requires twice daily parenteral injections. Enfuvirtide is associated with rare (&#x0003c;1%) instances of hypersensitivity reactions with eosinophilia, rash and systemic symptoms which can be accompanied by transient serum aminotransferase elevations, but other symptoms of hypersensitivity dominate the clinical picture.</p><p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p></div><div id="Enfuvirtide.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>Enfuvirtide is a polypeptide and is catabolized to its constituent amino acids and rapidly cleared from the circulation. Hepatic metabolism is minimal and enfuvirtide does not affect the CYP 450 system.</p></div><div id="Enfuvirtide.Outcome_and_Management"><h3>Outcome and Management</h3><p>If enfuvirtide hepatotoxicity occurs independent of minor aminotransferase elevations accompanying hypersensitivity reactions, it must be rare. Nevertheless, the product label for enfuvirtide mentions the possibility of toxic hepatitis and steatosis.</p><p>Drug Class: <a href="/books/n/livertox/AntiviralAgents/">Antiviral Agents</a></p></div></div><div id="Enfuvirtide.CASE_REPORT"><h2 id="_Enfuvirtide_CASE_REPORT_">CASE REPORT</h2><div id="Enfuvirtide.Case_1._Serum_enzyme_elevati"><h3>Case 1. Serum enzyme elevations during enfuvirtide/tipranavir/ritonavir therapy.</h3><p>[Modified from: J&#x000fc;lg B, Bogner JR, Goebel FD. Severe hepatotoxicity associated with the combination of enfuvirtide and tipranavir/ritonavir: case report. AIDS 2006; 20:1563. <a href="https://www.ncbi.nlm.nih.gov/pubmed/16847416" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>]</p><p>A 52 year old man with long standing HIV-HBV coinfection and exposure to multiple antiretroviral agents, developed serum aminotransferase elevations 2 weeks after having tipranavir/ritonavir added to a chronic regimen of zidovudine, lamivudine and enfurvitide. Serum enzymes, which had been normal before therapy, included <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> 538 U/L and <a class="def" href="/books/n/livertox/glossary/def-item/glossary.gamma-glutamyl-transpeptidase-ggt-/">GGT</a> 238 U/L. A liver biopsy was done that showed mild hepatitis and no steatosis. At the patient&#x02019;s request, enfuvirtide rather than tipranavir was stopped, and serum enzymes decreased by 50%. Serum GGT levels increased and at this point, tipranavir was stopped, whereupon all liver tests returned to normal during the next 4 weeks. Serial levels of HBV DNA were not available, but at the height of the enzyme elevations, HBV DNA was 20,000 copies/mL.</p><div id="Enfuvirtide.Key_Points"><h4>Key Points</h4><div id="Enfuvirtide.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548862/table/Enfuvirtide.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Enfuvirtide.T1_lrgtbl__"><table><thead><tr><th id="hd_h_Enfuvirtide.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Medication:</th><td rowspan="1" colspan="1" style="vertical-align:top;">Tipranavir/ritonavir</td></tr></thead><tbody><tr><th headers="hd_h_Enfuvirtide.T1_1_1_1_1" id="hd_b_Enfuvirtide.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</th><td headers="hd_b_Enfuvirtide.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Hepatocellular (R=5.5, based upon <a class="def" href="/books/n/livertox/glossary/def-item/glossary.gamma-glutamyl-transpeptidase-ggt-/">GGT</a> results)</td></tr><tr><th headers="hd_h_Enfuvirtide.T1_1_1_1_1" id="hd_b_Enfuvirtide.T1_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">Severity:</th><td headers="hd_b_Enfuvirtide.T1_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">Mild (<a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> elevations without jaundice)</td></tr><tr><th headers="hd_h_Enfuvirtide.T1_1_1_1_1" id="hd_b_Enfuvirtide.T1_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Enfuvirtide.T1_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;">2 weeks</td></tr><tr><th headers="hd_h_Enfuvirtide.T1_1_1_1_1" id="hd_b_Enfuvirtide.T1_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</th><td headers="hd_b_Enfuvirtide.T1_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;">4 weeks</td></tr><tr><th headers="hd_h_Enfuvirtide.T1_1_1_1_1" id="hd_b_Enfuvirtide.T1_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</th><td headers="hd_b_Enfuvirtide.T1_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">Ritonavir, zidovudine, lamivudine, enfurvitide</td></tr></tbody></table></div></div></div><div id="Enfuvirtide.Comment"><h4>Comment</h4><p>A complex course in a patient with multidrug resistant HIV infection on five antiretroviral agents. Serum <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> levels rose after addition of tipranavir to his chronic regimen. Stopping enfuvirtide was followed by partial improvement in liver tests, but complete resolution came only with stopping tipranavir. Tipranavir with low dose ritonavir has been associated with prominent ALT elevations (at least 5 times the upper limit of the normal range) in up to 10% of patients. Thus, enfuvirtide may have promoted the hepatotoxicity of tipranavir, but the effect was minor if present at all. In this instance, the enzyme elevations did not resolve until tipranavir was stopped. In the absence of serial testing of serum enzymes, bilirubin, HIV levels, CD4 counts as well as HBV DNA (with HBeAg, anti-HBe and IgM anti-HBc), the role of an exacerbation of the underlying chronic hepatitis B caused by immune reconstitution cannot be excluded.</p></div></div></div><div id="Enfuvirtide.PRODUCT_INFORMATION"><h2 id="_Enfuvirtide_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="Enfuvirtide.BPI" class="box"><p><b> REPRESENTATIVE TRADE NAMES</b></p><p>Enfuvirtide &#x02013; Fuzeon&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antiviral Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Enfuvirtide" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="Enfuvirtide.CHEMICAL_FORMULA_AND_STRUCTU"><h2 id="_Enfuvirtide_CHEMICAL_FORMULA_AND_STRUCTU_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Enfuvirtide.T2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548862/table/Enfuvirtide.T2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Enfuvirtide.T2_lrgtbl__"><table><thead><tr><th id="hd_h_Enfuvirtide.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_Enfuvirtide.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Enfuvirtide.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Enfuvirtide.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Enfuvirtide.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Enfuvirtide</td><td headers="hd_h_Enfuvirtide.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135078459" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">159519-65-0</a></td><td headers="hd_h_Enfuvirtide.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C204-H301-N51-O64</td><td headers="hd_h_Enfuvirtide.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div></div></div><div id="Enfuvirtide.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Enfuvirtide_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 10 February 2018</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Enfuvirtide.R1">N&#x000fa;&#x000f1;ez M. Hepatic toxicity of antiviral agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2011, pp. 567-91.<div><i>(Review of hepatotoxicity of antiviral medications; based upon product labeling, enfuvirtide is shown as having a ~6% incidence of "severe" drug induced liver injury).</i></div></div></li><li><div class="bk_ref" id="Enfuvirtide.R2">Flexner C. Antiretroviral agents and treatment of HIV infection. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1623-1664.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Enfuvirtide.R3"><a href="https://aidsinfo.nih.gov/guidelines" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://aidsinfo<wbr style="display:inline-block"></wbr>â€‹.nih.gov/guidelines</a>.<div><i>(Regularly updated guidelines on use of antiretroviral agents in adults, adolescents and children with HIV infection).</i></div></div></li><li><div class="bk_ref" id="Enfuvirtide.R4">Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, Goodgame JC, et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide(T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002; 18: 685-93.  [<a href="/pubmed/12167274" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12167274</span></a>]<div><i>(Analysis of safety and efficacy of enfuvirtide in 78 patients with HIV treated for 28 days; "no significant or clinically meaningful changes or differences between dosage groups in clinical chemistry results").</i></div></div></li><li><div class="bk_ref" id="Enfuvirtide.R5">Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, et al.; TORO 1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348: 2175-85.  [<a href="/pubmed/12637625" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12637625</span></a>]<div><i>(Large, registration trial of adding enfuvirtide to an "optimized" regimen in 501 patients with HIV infection and resistance to conventional antiretrovirals; updated combined safety analysis in 663 patients on enfuvirtide found 2 instances of hypersensitivity, but no mention of hepatotoxicity and rates of laboratory abnormalities were not different in enfuvirtide as control [optimal regimen] patients).</i></div></div></li><li><div class="bk_ref" id="Enfuvirtide.R6">Lazzarin A, Clotet B, Cooper D, Reynes J, Arast&#x000e9;h K, Nelson M, Katlama C, et al.; TORO 2 Study Group. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348: 2186-95.  [<a href="/pubmed/12773645" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12773645</span></a>]<div><i>(Controlled trial of adding enfuvirtide to an "optimized" regimen in 512 patients with HIV infection and resistance to conventional antiretrovirals; updated combined safety analysis for 813 patient-years of exposure reported: "No consistent pattern was evident to suggest a definitive association of enfurvitide with any particular laboratory abnormality").</i></div></div></li><li><div class="bk_ref" id="Enfuvirtide.R7">Hardy H, Skolnik PR. Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection. Pharmacotherapy 2004; 24: 198-211.  [<a href="/pubmed/14998221" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14998221</span></a>]<div><i>(Review of structure, pharmacology, mechanism of action, clinical efficacy and safety of enfuvirtide: 36-amino acid synthetic peptide derived from sequence motif of HIV protein gp41, a transmembrane protein necessary for HIV fusion to CD4 cells; found to suppress HIV in culture and in humans, but must be given by injection; metabolized to amino acids which are probably reused; large registration trials [TORO-1 and 2] demonstrated efficacy and that side effects were similar to controls except for injection site reactions [97% vs nil] and eosinophilia [10% vs 2.4%], but not associated with systemic features and no mention of hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Enfuvirtide.R8">Church JA, Hughes M, Chen J, Palumbo P, Mofenson LM, Delora P, Smith E, et al.; Pediatric AIDS Clinical Trials Group P1005 Study Team. Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. Pediatr Infect Dis J 2004; 23: 713-8.  [<a href="/pubmed/15295220" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15295220</span></a>]<div><i>(Analysis of efficacy and safety of up to 96 weeks of enfuvirtide therapy in 14 children with HIV infection; no mention of hepatotoxicity and no instances of liver test abnormalities above 5 times ULN).</i></div></div></li><li><div class="bk_ref" id="Enfuvirtide.R9">Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, et al. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr 2005; 40: 413-21.  [<a href="/pubmed/16280695" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16280695</span></a>]<div><i>(Follow up to 48 weeks of patients in registration trials of enfuvirtide [Lazzarin 2003 and Lalezari 2003]; no mention of hepatotoxicity or rates of ALT elevations; eosinophilia in ~12.5% per year; 6 cases of hypersensitivity, 5 recurring with rechallenge and some patients developed "elevated serum liver transaminases").</i></div></div></li><li><div class="bk_ref" id="Enfuvirtide.R10">J&#x000fc;lg B, Bogner JR, Goebel FD. Severe hepatotoxicity associated with the combination of enfuvirtide and tipranavir/ritonavir: case report. AIDS 2006; 20: 1563.  [<a href="/pubmed/16847416" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16847416</span></a>]<div><i>(52 year old man with HIV-HBV co-infection developed marked increase in ALT [538 U/L] without jaundice, 2 weeks after adding tipranavir and ritonavir to a regimen of zidovudine, lamivudine and enfuvirtide, resolving in 4 weeks of stopping; possibly related to effects of enfuvirtide on drug levels, no analysis of HBV reactivation and lamivudine resistance: Case 1).</i></div></div></li><li><div class="bk_ref" id="Enfuvirtide.R11">Shibuyama S, Gevorkyan A, Yoo U, Tim S, Dzhangiryan K, Scott JD. Understanding and avoiding antiretroviral adverse events. Curr Pharm Des 2006; 12: 1075-90.  [<a href="/pubmed/16515487" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16515487</span></a>]<div><i>(Class wide adverse effects of antiretroviral agents include lactic acidosis for di-deoxynucleosides, rash and hepatitis for nonnucleoside reverse transcriptase inhibitors and lipodystrophy for protease inhibitors; fusion inhibitors such as enfuvirtide are well tolerated, but associated with frequent sometimes troubling injection site reactions and eosinophilia ).</i></div></div></li><li><div class="bk_ref" id="Enfuvirtide.R12">Raffi F, Battegay M, Rusconi S, Opravil M, Blick G, Steigbigel RT, Kraft M, et al. Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. AIDS 2007; 21: 1977-80.  [<a href="/pubmed/17721109" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17721109</span></a>]<div><i>(Analysis of clinical trial of tipranavir/ritonavir [r] vs comparator protease inhibitors/r who received enfuvirtide; tipranavir [+31%], lopinavir [+19%] and saquinavir levels [+39%] were higher in enfuvirtide treated, but rates of ALT elevations above 5 times ULN were lower in the enfuvirtide treated [6.5% vs 13%; 1% vs 2.5%; 0.9% vs 1.6%]).</i></div></div></li><li><div class="bk_ref" id="Enfuvirtide.R13">Reynes J, Arast&#x000e9;h K, Clotet B, Cohen C, Cooper DA, Delfraissy JF, Eron JJ, et al. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS 2007; 21: 533-43.  [<a href="/pubmed/17711378" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17711378</span></a>]<div><i>(In follow up analysis of the registration trials of enfuvirtide extended to 96 weeks, no new safety issues emerged; no mention of hepatotoxicity or ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Enfuvirtide.R14">DeJesus E, Gottlieb MS, Gathe JC Jr, Greenberg ML, Guittari CJ, Zolopa AR. Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study. Antimicrob Agents Chemother 2008; 52: 4315-9.  [<a href="/pmc/articles/PMC2592875/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2592875</span></a>] [<a href="/pubmed/18809940" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18809940</span></a>]<div><i>(Among 137 patients with HIV infection receiving enfuvirtide with darunavir/ritonavir for for 24 weeks, there were 4 discontinuations and 18 serious adverse events, none were liver related; no mention of ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Enfuvirtide.R15">Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, et al.; International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300: 555-70.  [<a href="/pubmed/18677028" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18677028</span></a>]<div><i>(Updated recommendations on use of antiviral therapy in adults with HIV infection including use of recently approved agents: raltegravir, maraviroc and etravirine).</i></div></div></li><li><div class="bk_ref" id="Enfuvirtide.R16">Wright D, Rodriguez A, Godofsky E, Walmsley S, Labriola-Tompkins E, Donatacci L, Shikhman A, et al. Efficacy and safety of 48 weeks of enfuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patients. HIV Clin Trials 2008; 9: 73-82.  [<a href="/pubmed/18474492" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18474492</span></a>]<div><i>(Comparison of once vs twice daily enfuvirtide added to an optimized regimen for 48 weeks in 61 patients with HIV infection; the two regimens had similar efficacy and safety; no mention of hepatotoxicity or ALT elevations). </i></div></div></li><li><div class="bk_ref" id="Enfuvirtide.R17">Drugs for HIV infection. Treat Guidel Med Lett 2014; 12 (138): 7-16;  [<a href="/pubmed/24457549" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24457549</span></a>]<div><i>(Concise review of drugs for HIV infection discusses enfuvirtide as the only fusion inhibitor approved for use in the US and mentions adverse side effects of local pain and irritation, eosinophilia, hypersensitivity reactions and increased rate of bacterial pneumonia, but does not mention ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Enfuvirtide.R18">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A Chirino R, et al. Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. Ann Hepatol 2014; 13: 231-9.  [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i> (Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, 5 of which were attributed to antiretroviral agents, including lamivudine, zidovudine and nevirapine, but not enfuvirtide).</i></div></div></li><li><div class="bk_ref" id="Enfuvirtide.R19">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52.e7.  [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 12 [1.3%] were attributed to antiretroviral medications, but none specifically to enfuvirtide).</i></div></div></li><li><div class="bk_ref" id="Enfuvirtide.R20">Xu F, Acosta EP, Liang L, He Y, Yang J, Kerstner-Wood C, Zheng Q, et al. Current status of the pharmacokinetics and pharmacodynamics of HIV-1 entry inhibitors and HIV therapy. Curr Drug Metab 2017; 18: 769-81.  [<a href="/pubmed/28738768" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28738768</span></a>]<div><i>(Summary of the mechanism of action, pharmacokinetics and safety of enfuvirtide; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Enfuvirtide.R21">de Castro N, Braun J, Charreau I, Lafeuillade A, Viard JP, Allavena C, Aboulker JP, et al.; EASIER ANRS 138 study group. Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial. AIDS Res Ther 2016; 13: 17.  [<a href="/pmc/articles/PMC4818923/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4818923</span></a>] [<a href="/pubmed/27042193" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27042193</span></a>]<div><i> (Among 169 HIV infected patients on long term antiretroviral therapy who were either maintained on enfuvirtide or switched to raltegravir, serum ALT levels were more frequently elevated [above 3 times ULN] in those switched to raltegravir [7% vs 2%], but no patient developed clinically apparent liver injury and multivariate analysis suggested that tipranavir was more likely the cause of the abnormalities).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548862</span><span class="label">PMID: <a href="/pubmed/31644169" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31644169</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Enflurane/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Entacapone/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548862&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548862/?report=reader">PubReader</a></li><li><a href="/books/NBK548862/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548862" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548862" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Enfuvirtide. [Updated 2018 Feb 10].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548862/pdf/Bookshelf_NBK548862.pdf">PDF version of this page</a> (101K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=(Enfuvirtide/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Enfuvirtide: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Enfuvirtide" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Enfuvirtide: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4861818" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4861818" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4861818" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643636" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Raltegravir</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Raltegravir<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/15110129" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Enfuvirtide: a fusion inhibitor for the treatment of HIV infection.</a><span class="source">[Clin Ther. 2004]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Enfuvirtide: a fusion inhibitor for the treatment of HIV infection.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Fung HB, Guo Y. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Ther. 2004 Mar; 26(3):352-78. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27795437" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.</a><span class="source">[J Virol. 2017]</span><div class="brieflinkpop offscreen_noflow">A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Xiong S, Borrego P, Ding X, Zhu Y, Martins A, Chong H, Taveira N, He Y. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Virol. 2017 Jan 1; 91(1). Epub 2016 Dec 16.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/15231762" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Resistance to enfuvirtide, the first HIV fusion inhibitor.</a><span class="source">[J Antimicrob Chemother. 2004]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Resistance to enfuvirtide, the first HIV fusion inhibitor.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Greenberg ML, Cammack N. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Antimicrob Chemother. 2004 Aug; 54(2):333-40. Epub 2004 Jul 1.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/15295220" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children.</a><span class="source">[Pediatr Infect Dis J. 2004]</span><div class="brieflinkpop offscreen_noflow">Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Church JA, Hughes M, Chen J, Palumbo P, Mofenson LM, Delora P, Smith E, Wiznia A, Hawkins E, Sista P, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Pediatr Infect Dis J. 2004 Aug; 23(8):713-8. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31644169" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31644169" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=60468146a19b7255ae18aa17">Enfuvirtide - LiverTox</a><div class="ralinkpop offscreen_noflow">Enfuvirtide - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T14:55:50-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal103&amp;ncbi_phid=CE8A34C804654F61000000000A580335&amp;ncbi_session=CE8A34C804681451_2648SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548862%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548862&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548862/&amp;ncbi_pagename=Enfuvirtide - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8A34C804681451_2648SID /projects/books/PBooks@9.2 portal103 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>